Better Health for All

Larimar Therapeutics' sole product, nomlabofusp, is a therapy for Friedreich's ataxia (FA), a rare, progressive, and fatal disease.

The therapy has demonstrated revolutionary clinical improvements, including a median 2.25-point mFARS improvement after one year compared to a 1-point worsening in natural history, and 100% of participants achieved skin frataxin levels comparable to asymptomatic carriers by six months. As a pre-revenue company focused entirely on this health-positive therapy, it has no revenue from harmful products. However, the company has a severe safety record, with 7 anaphylaxis events reported among 65 dosed patients in the open-label study, an adverse event rate exceeding 100 per million users. Additionally, the FDA placed a clinical hold on the program in May 2021 due to mortalities at the highest dose levels in a non-human primate toxicology study. While the company has since modified its starting dose regimen, and the FDA has agreed to the proposal, these incidents are significant. The Schall Law Firm announced a securities fraud investigation in October 2025, citing potential violations of securities laws related to disclosures, indicating issues with risk transparency. Larimar plans to expand its clinical program to include adolescent (12-17 years old) and pediatric (2-11 years old) patients, with approximately 50% of current study participants being non-ambulatory at baseline. The company's research and development expenses increased by $48.3 million year-over-year in the first nine months of 2025, and it plans to use its protein replacement therapy platform to target additional rare diseases, demonstrating a high commitment to health innovation. The FDA's agreement to a modified dosing regimen and consideration of skin frataxin concentration as a surrogate endpoint for accelerated approval indicates strong regulatory engagement in the clinical trial process.

Fair Money & Economic Opportunity

Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases, specifically Friedreich's ataxia.

The company's activities primarily revolve around research, development, and clinical testing of pharmaceutical products. The ethical value 'Fair Money & Economic Opportunity' assesses activities related to lending, insuring, moving, or storing money, and how financial institutions democratize access to fair financial services. As Larimar Therapeutics is not a financial institution and does not offer lending, deposit, or other financial services to consumers, all KPIs under this value are not applicable to its core business model. Therefore, all KPIs are assigned a score of 0, indicating that the firm does not offer the relevant financial services or products.

Fair Pay & Worker Respect

As of December 31, 2024, Larimar Therapeutics, Inc. employed 65 full-time employees in the United States, none of whom are represented by a labor organization or under any collective-bargaining arrangements.

The company states it strives to provide a safe and rewarding workplace with strong compensation, benefits, paid time-off, and health and wellness programs. Its Code of Business Conduct and Ethics, effective February 27, 2025, forbids discrimination based on criteria prohibited by law, including race, sex, and age, and aims to ensure fair and respectful treatment of employees. The Compensation Committee oversees compensation structure to attract and retain key personnel and align management interests with stockholders.

Honest & Fair Business

Larimar Therapeutics has a whistleblower policy, effective February 27, 2025, that applies to all employees, officers, and directors.

It includes an anonymous company hotline and explicitly states that the company will not tolerate retaliation for good faith reports. Employees also have the right to report possible violations of state or federal law or regulation to any governmental agency or entity, or self-regulatory organization, and cannot be retaliated against for doing so. Employees must sign an annual certification stating they have received, read, understand, and agree to comply with the Code of Business Conduct and Ethics. The Audit Committee is responsible for establishing procedures for confidential, anonymous submission of concerns regarding accounting or auditing matters. The company has a Clawback Policy that addresses financial restatements, requiring recovery of compensation in the event of a restatement due to material noncompliance with financial reporting requirements. No financial restatements are mentioned in the provided articles. Regarding board independence, 5 out of 6 current directors are determined to be independent, as defined by Nasdaq rules, which means approximately 83.3% of the board is conflict-free. The Audit Committee must consist of at least three independent members. The company's Code of Conduct covers compliance with legal and regulatory requirements, which implicitly includes anti-corruption measures. The Foreign Corrupt Practices Act (FCPA) is mentioned as prohibiting U.S. businesses from bribery. However, there is no explicit detail on the policy's scope (e.g., international operations), training frequency, or effectiveness metrics. The company relies on third-party supply and manufacturing partners for drug supplies and uses third-party manufacturers for clinical packaging, storage, and distribution. PricewaterhouseCoopers LLP serves as the independent registered public accounting firm for the 2024 fiscal year. Radford, an operating unit of Aon plc, serves as an independent compensation consultant for executive compensation. The Audit Committee is directly responsible for the appointment, retention, and compensation of the independent auditors.

No War, No Weapons

Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for rare diseases.

The provided evidence consistently states that the company is not a defense contractor and has no involvement in defense-related activities, arms contracts, or military sales. Consequently, all KPIs related to 'No War, No Weapons' are explicitly noted as 'Not applicable' in the company's annual report, as its core business does not involve dual-use technologies, sales to embargoed regimes, peacebuilding initiatives, conflict-zone divestment, military-related lobbying, or procurement from conflict areas. There is no evidence of any activities that would require oversight of defense business, export certifications for military goods, human rights due diligence in conflict zones, Arms Trade Treaty compliance, AI military safeguards, or ethical red lines for weapons.

Planet-Friendly Business

No specific, concrete data points were found across the provided articles for any of the 'Planet-Friendly Business' KPIs. The articles primarily consist of financial filings and general company descriptions, none of which contain quantifiable information on environmental metrics such as emissions, renewable energy use, water consumption, waste diversion, green building certifications, or climate-related policies and initiatives.

A mention of 'proceedings regarding compliance with Environmental Laws' was noted, but without a specific number of violations or their nature, it cannot be scored against the 'annual_env_compliance_violations' KPI.

Respect for Cultures & Communities

No data relevant to the 'Respect for Cultures & Communities' value or its specified key metrics is presented in the provided article for Larimar Therapeutics, Inc.

The article focuses on the company's pipeline and clinical trials for nomlabofusp, without addressing any community engagement, cultural impact, or related initiatives.

Safe & Smart Tech

The company has not identified any cybersecurity incidents or threats that have materially affected it.

Its privacy policy, effective April 11, 2025, outlines user rights for California residents (CCPA) to know, delete, and opt-out of sale, and for EU residents (GDPR) to access, rectify, erase, and restrict processing. The company states it is the 'controller' of personal data for EU residents and transfers data to the US through appropriate safeguards, and mentions compliance with GDPR and CCPA. Employee training is part of the company's security measures. Access controls are implemented as part of security measures. The company conducts scans of certain environments and other tests to identify and assess risks. Personal information is retained as long as necessary to fulfill the purpose for which it was collected, or as required by applicable laws or regulation.